UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 19.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 119,052 shares of the company's stock after purchasing an additional 19,315 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.16% of SpringWorks Therapeutics worth $4,301,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of SpringWorks Therapeutics by 6.6% in the 4th quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company's stock valued at $258,650,000 after purchasing an additional 445,593 shares in the last quarter. Boxer Capital Management LLC bought a new position in shares of SpringWorks Therapeutics during the 4th quarter worth approximately $123,620,000. Pictet Asset Management Holding SA raised its stake in shares of SpringWorks Therapeutics by 24.2% during the 4th quarter. Pictet Asset Management Holding SA now owns 2,391,412 shares of the company's stock worth $86,402,000 after acquiring an additional 465,494 shares in the last quarter. Capital International Investors raised its stake in shares of SpringWorks Therapeutics by 92.7% during the 4th quarter. Capital International Investors now owns 2,361,746 shares of the company's stock worth $85,330,000 after acquiring an additional 1,136,079 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC raised its stake in shares of SpringWorks Therapeutics by 0.5% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,499,134 shares of the company's stock worth $54,164,000 after acquiring an additional 7,072 shares in the last quarter.

Analysts Set New Price Targets

SWTX has been the subject of several recent analyst reports. Evercore ISI lowered shares of SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. HC Wainwright reiterated a "neutral" rating and set a $47.00 price objective (down previously from $74.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, April 30th. Guggenheim restated a "neutral" rating and set a $47.00 price target on shares of SpringWorks Therapeutics in a research note on Monday, May 12th. Barclays restated an "equal weight" rating and set a $47.00 price target (down previously from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Finally, Cowen lowered shares of SpringWorks Therapeutics to a "hold" rating in a research note on Tuesday, April 29th. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $52.57.

SpringWorks Therapeutics Price Performance

SpringWorks Therapeutics stock traded up $0.09 during mid-day trading on Thursday, reaching $46.80. 4,053,081 shares of the company traded hands, compared to its average volume of 2,271,707. SpringWorks Therapeutics, Inc. has a fifty-two week low of $28.21 and a fifty-two week high of $62.00. The company has a market capitalization of $3.53 billion, a price-to-earnings ratio of -13.45 and a beta of 0.77. The firm's fifty day moving average is $43.26 and its two-hundred day moving average is $43.38.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.30). The business had revenue of $49.09 million during the quarter, compared to analysts' expectations of $64.19 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. As a group, equities research analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.